Digital PET and detection of recurrent prostate cancer: what have we gained, and what is still missing?

Defined by the TIME magazine 'medical invention of the year 2000,' positron emission computed tomography (PET/CT) has experienced impressive improvements in technology and clinical applications over time. In recent years, silicon photomultipliers (SiPMs) detectors, characterized by excellent intrinsic time resolution and high photon-detection efficiency, have been introduced as an alternative to the classic photomultiplier tubes (PMTs), thus moving the field of PET technology forward and leading to the so-called digital PET/CT (dPET/CT). On the other side, the radiopharmaceutical ⁶⁸Ga-PSMA-11, approved by the Food and Drug Administration in December 2020, proved to strongly impact prostate cancer (PCa) diagnosis and management. In the study under evaluation, Alberts et al. retrospectively compared the performance of dPET/CT and PMTs-based PET/CT, namely analogue PET/CT (aPET/CT), in two cohorts, each one including 65 patients undergoing PET/CT with ⁶⁸Ga-PSMA-11 for suspected recurrent PCa. The authors found that dPET/CT presented a higher detection rate of pathological lesions with respect to aPET/CT. Of note, dPET/CT's higher sensitivity results are associated with an increased true-positive rate and high inter-reader agreement. This report underscores how innovative PET/CT instrumentation, by utilizing novel radiopharmaceuticals targeting specific metabolic/molecular signatures expressed by PCa, may represent a successful weapon in uro-oncology.